Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALOX5AP | P20292 | 4/20 | 0.41 |
| ▸ | FEN1 | P39748 | 4/20 | 0.41 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.41 |
| ▸ | SMARCA2 | P51531 | 1/20 | 0.39 |
| ▸ | SMARCA4 | P51532 | 1/20 | 0.39 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.39 |
| ▸ | TRPV3 | Q8NET8 | 1/20 | 0.39 |
| ▸ | HPGDS | O60760 | 1/20 | 0.38 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 6/20 | 0.37 |
| ▸ | PARP1 | P09874 | 1/20 | 0.37 |
| ▸ | MAP3K12 | Q12852 | 1/20 | 0.37 |
| ▸ | HTR6 | P50406 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5432419 | 0.90 | IKBKB (0.44) | ALOX5APFEN1PRMT5SMARCA2SMARCA4 | |
| SCHEMBL5425664 | 0.88 | SMARCA2 (0.44) | ALOX5APFEN1PRMT5SMARCA2SMARCA4 | |
| SCHEMBL5424220 | 0.88 | PRMT5 (0.51) | ALOX5APFEN1PRMT5HPGDSIKBKB | |
| SCHEMBL5427548 | 0.88 | PRMT5 (0.41) | ALOX5APFEN1PRMT5SMARCA2SMARCA4 | |
| SCHEMBL5441000 | 0.86 | TRPV3 (0.42) | ALOX5APFEN1PRMT5SMARCA2SMARCA4 | |
| SCHEMBL5424154 | 0.86 | PRMT5 (0.48) | ALOX5APFEN1PRMT5SMARCA2SMARCA4 | |
| SCHEMBL5429334 | 0.85 | USP30 (0.41) | ALOX5APFEN1PRMT5SMARCA2SMARCA4 | |
| SCHEMBL5422694 | 0.84 | PRMT5 (0.42) | ALOX5APFEN1PRMT5SMARCA2SMARCA4 | |
| SCHEMBL5437874 | 0.83 | KDM4E (0.40) | ALOX5APFEN1PRMT5SMARCA2SMARCA4 | |
| SCHEMBL5427341 | 0.81 | SMARCA2 (0.40) | ALOX5APFEN1PRMT5SMARCA2SMARCA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | ASTELLAS PHARMA INC. (JP) | 2007-11-15 | — | — | US | disclosed |
| EP-1736472-A1 | 2-AMINOPYRIDINE DERIVATIVE | Astellas Pharma Inc. (JP) | 2006-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265289-A1 | 2-Aminopyrimidine Derivative | NFKBIA, IKBKG, NFKB2 | ALOX5AP 751/4885FEN1 1849/4885PRMT5 324/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.